Peter Hopewood, MD
Surgery · Falmouth, MANPI 1275607525
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Integra Lifesciences Corporation at 37.4% of the total. Reporting peaked in 2022 at $294 and has fallen 54.2% since, to $134 in 2025. That places this record below the midpoint for surgery clinicians in MA, where the typical reported total is $1,048.
Across 26 payments — averaging $28.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Integra Lifesciences Corporation$276
- TELA Bio, Inc.$90
- TEI Biosciences Inc$68
- Kerecis Limited$67
- Solventum Corporation$53
- Boston Scientific$47
- plus $137 from 5 others
What the payments were for
- Food & beverage$738100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Integra Lifesciences Corporation | 9 | $276 |
| TELA Bio, Inc. | 3 | $90 |
| TEI Biosciences Inc | 3 | $68 |
| Kerecis Limited | 2 | $67 |
| Solventum Corporation | 2 | $53 |
| Boston Scientific | 2 | $47 |
| Smith+Nephew | 1 | $44 |
| CSL Behring | 1 | $33 |
| Myriad Genetic Laboratories, Inc. | 1 | $25 |
| Heron Therapeutics, Inc. | 1 | $18 |
| Getinge USA Sales, LLC | 1 | $17 |
How this compares
$738 in reported general payments places this provider in the 45th percentile of 694 surgery providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 11 | $6,964 |
| Letrozole | 21 | $581 |
| Oxycodone Hcl | 29 | $100 |
| Tramadol Hcl | 35 | $56 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $39 |
Paid to pharmacies, not to this prescriber.
Other surgery in Falmouth
- Michael TarnoffBoston$1.4M
- Omar KudsiBoston$886K
- Philip CohenBrockton$280K
- Ankit MehtaBoston$278K
- Mark ConradMethuen$187K
- James HermenegildoFall River$178K
- Richard EngelmanSpringfield$167K
- Reuben ShinBurlington$158K
- Richard BirkettBeverly$93K
- Johannes KratzBoston$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.